Medication info
X1 Tablet 5/80 mg

X1 Tablet 5/80 mg

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tabletAmlodipine Adipate›6.79mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Dark yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3), 30 tablets/bottle, 90 tablets/bottle
Approval status
Active

MFDS item code 201308289 · Approved 2013.07.18 · Insurance code 640006590

Summary

Main use
Treatment of essential hypertension inadequately controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using an individual component as follows, switching directly to this medicine may be considered. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). However, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients receiving dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Treatment of essential hypertension inadequately controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower and control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or valsartan.

How to take

Adult dose

The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using an individual component as follows, switching directly to this medicine may be considered. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). However, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients receiving dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnant. It should not be taken by individuals who have allergies to its active ingredients or similar components, pregnant women, patients with severe kidney or liver diseases, or certain diabetic patients. Patients with fluid or sodium deficiency should manage their condition well before taking this medication, and blood pressure and condition should be closely monitored during use. Patients with high potassium levels should be cautious when taking this medication along with potassium-containing drugs or supplements, and regular blood tests to check potassium levels are necessary. Patients with narrowed renal arteries or those who have had kidney transplants require careful monitoring after taking this medication due to potential effects on kidney function. If symptoms of angioedema appear, discontinue use immediately and do not take it again. Patients with heart failure or myocardial infarction should also closely monitor kidney function and symptoms while taking this medication. As with other vasodilators, caution is needed for patients with certain heart conditions such as aortic stenosis. Combining this medication with angiotensin receptor blockers, ACE inhibitors, or aliskiren can increase the risk of hypotension, worsening kidney function, and hyperkalemia, so combination therapy should be avoided or strictly monitored. Dizziness or fatigue may occur while taking this medication, so caution is needed when driving or operating machinery. This medication may interact with other drugs, particularly potassium supplements, diuretics, NSAIDs, certain antibiotics, simvastatin, and CYP3A4 inhibitors, so consulting with a healthcare professional is advised when taking these together. Breastfeeding women are not recommended to take this medication, and its safety and efficacy have not been sufficiently established for children under 18, so its use is not recommended in this age group. In case of overdose, symptoms like hypotension and cardiac function abnormalities may occur, so immediate medical attention is required.

Side effects

Pharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, orthostatic dizziness, paresthesia, vertigo, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, sore throat and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, rash, erythema, hyperhidrosis, rash, itching, joint swelling, lumbar pain, arthritis, muscle spasm, lethargy, polyuria, nocturia, erectile dysfunction, edema, local edema, facial edema, peripheral edema, fatigue, flushing, weakness, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, angioedema, myalgia, renal failure, renal damage, increased serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infection, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremor, sensory impairment, dysgeusia, peripheral neuropathy, hypertonia, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, urination disorders, enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, elevated liver enzymes, leukopenia, thrombocytopenia, confusion, exfoliative dermatitis, Stevens-Johnson syndrome, photosensitivity reaction, toxic epidermal necrolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Dark yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3), 30 tablets/bottle, 90 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.